返回 
加入收藏
“BRAND”药学服务模式用于驱动基因阳性晚期NSCLC患者的实践研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | “BRAND”药学服务模式用于驱动基因阳性晚期NSCLC患者的实践研究 |
| TITLE： | Practical study on the application of “BRAND”pharmaceutical care model in advanced NSCLC patients with positive driver genes |
| 摘要： | 目的 构建针对驱动基因阳性晚期非小细胞肺癌（NSCLC）患者的“BRAND”药学服务模式，为临床开展精准化、个体化肿瘤药学服务提供理论与实践参考。方法根据纳排标准收集2023年1月至2024年5月在我院呼吸与危重症医学科住院的患者100例，将患者随机分为对照组和干预组，每组50例。对照组接受常规药学服务，干预组接受“BRAND”药学服务（收集患者基本信息、回顾疾病治疗相关信息、精准用药评估、明确下一步个体化药学服务方案、实施用药指导及随访管理）。每3周为1个周期，研究共持续4个周期。比较干预前后两组患者的用药依从性、生活质量、实验室检验指标、药物相关不良事件发生率和患者满意度，进行效果评价。结果干预12周后，与对照组比较，干预组患者的用药依从性、认知功能、社会功能、满意度均显著提高（P＜0.05），疲乏、便秘的严重程度及药物相关不良事件发生率均显著降低（P＜0.05），实验室检验指标差异无统计学意义（P＞0.05）。结论“BRAND”药学服务模式可有效提高驱动基因阳性晚期NSCLC患者的用药依从性、改善其生活质量，为临床药师开展标准化、高质量的药学服务提供了可行路径。 |
| ABSTRACT： | OBJECTIVE To establish a “BRAND” pharmaceutical care model for advanced non-small cell lung cancer （NSCLC） patients with positive driver genes， providing theoretical and practical references for the clinical implementation of precise and individualized oncology pharmaceutical care. METHODS One hundred patients admitted to the department of pulmonary and critical care medicine in our hospital from January 2023 to May 2024 were collected meeting the inclusion and exclusion criteria. Patients were randomly divided into control group and intervention group， with 50 patients in each group. The control group received routine pharmaceutical care， while the intervention group received pharmaceutical care under the “BRAND” model （collecting patients’ basic information， reviewing disease treatment-related information， conducting precise medication assessments， formulating individualized pharmaceutical care plans for the next steps， and implementing medication guidance and follow-up management）. The study was conducted in a 3-week cycle for a total of 4 cycles. The medication compliance， quality of life， laboratory test indicators， incidence of drug-related adverse events and satisfaction of patients in both groups were compared before and after the intervention to evaluate the effects. RESULTS After 12 weeks of intervention， compared with the control group， the medication compliance， cognitive function， social function and satisfaction of patients in the intervention group were improved significantly （ P ＜0.05）； the severity of fatigue and constipation and the incidence of drug-related adverse events were significantly reduced （ P ＜0.05）， and there was no statistically significant difference in laboratory test indicators （ P ＞0.05）. CONCLUSIONS The “BRAND” pharmaceutical care model can effectively improve the medication compliance of patients with advanced NSCLC with positive driver genes and improve their quality of life. This study can provide a feasible path for clinical pharmacists to carry out standardized and high-quality pharmaceutical care. |
| 期刊： | 2026年第37卷第05期 |
| 作者： | 郁件康；龚伟；石金芳；唐婕；龚银华 |
| AUTHORS： | YU Jiankang，GONG Wei，SHI Jinfang，TANG Jie，GONG Yinhua |
| 关键字： | “BRAND”药学服务模式；驱动基因阳性；晚期；非小细胞肺癌；药学服务 |
| KEYWORDS： | “BRAND” pharmaceutical care model； positive driver gene； advanced stage； non-small cell lung cancer； |
| 阅读数： | 2 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
